# Endovia Health Sciences, Inc. (EDVA) · Edgar & Edgarette company card

> Endovia Health Sciences (EDVA) saw revenue fall 90.9% in FY2025 to $0 million, operating margin -19416% against a 12.2% median for beverages, equity -1584% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1553788 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/EDVA) · [JSON](https://www.pops4.com/boards/company/EDVA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $73,066 |
| Revenue growth, 1 year | -90.9% |
| Revenue growth per year | -71.7% |
| Operating margin | -19415.6% (prior year -1235.6%) |
| Net margin | -34601.8% |
| Operating cash flow | −$5M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $281,435 |
| Long-term debt | $3,418 |
| Total assets | $965,694 |
| Total equity | −$15M |
| Equity ÷ assets | -1584.4% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -819.93 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$4.8M in FY2025); operating loss: a margin of -19415.6% in FY2025; revenue is hard to predict: its 80% range is ±53%

## Edgarette's reading

Exposure: revenue $73K (FY2025), total debt $3K. Experience: revenue down 90.9% on the year, down 71.7% a year over 4 years; operating margin -19415.6%, down from -1235.6%. Soundness: equity -1584.4% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5K and $16K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5K to $18K. A statistical range, not company guidance. Against peers (9 filers, $50M+ revenue, beverages): operating margin -19415.6% against a 12.2% median; growth -90.9% against 1.9%.

Range logged 2026-09-26, receipt 67bbbefbdc7f0668, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226000516/0001731122-26-000516-index.htm))
- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-07-09 ([filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226000927/0001731122-26-000927-index.htm))
- Item NT 10-Q Late quarterly report notice: 3, latest 2026-08-17 ([filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001081/0001731122-26-001081-index.htm))
- Item 5.02 Director or officer change: 8, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226000851/0001731122-26-000851-index.htm))

## Recent filings

- DEF 14A · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001390/0001731122-26-001390-index.htm)
- S-1 · filed 2026-10-27 · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001378/0001731122-26-001378-index.htm)
- 8-K · filed 2026-10-27 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001375/0001731122-26-001375-index.htm)
- 8-K · filed 2026-10-15 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001347/0001731122-26-001347-index.htm)
- 8-K · filed 2026-10-06 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001320/0001731122-26-001320-index.htm)
- DEF 14A · filed 2026-10-05 · [filing](https://www.sec.gov/Archives/edgar/data/1553788/000173112226001316/0001731122-26-001316-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001553788.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1553788

## Cite

POPS4, Edgar & Edgarette: Endovia Health Sciences, Inc. (EDVA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/EDVA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.